The strongest version of this hypothesis is not that APOE4 makes all microglia generally bad phagocytes. It is that APOE4 pushes a subset of disease-associated, lipid-stressed microglia into a state where cholesterol esterification and neutral lipid storage compete with the lysosomal program needed for efficient fibrillar amyloid-beta processing. The analysis is valuable because it asks for subpopulation-level causality: which microglia, which lipid species, and which clearance step fail.
Mechanistic chain: APOE4 alters lipid handling and APOE receptor signaling, producing less effective lipid transport than APOE3. In amyloid-rich tissue, microglia must phagocytose plaques, traffic cargo through endolysosomal compartments, and survive sustained lipid/protein burden. If APOE4 increases cholesterol ester accumulation or lipid droplet load in a lipid-associated microglial substate, lysosomal membrane integrity and cathepsin activity could fall, lowering degradation even if initial particle uptake is not always reduced. This reconciles the hypothesis with APOE pathobiology reviews (PMID:36348357; PMID:31367008) and with TREM2-linked microglial amyloid clearance biology (DOI:10.1038/cr.2015.37).
The clean test is a single-cell multi-omic amyloid-clearance assay in APOE3/3 versus APOE4/4 microglia, ideally human iPSC microglia transplanted into amyloid mouse brain or co-cultured with human amyloid fibrils. Measure lipid droplets, cholesteryl esters, ABCA1/LXR target genes, lysosomal pH, cathepsin B/D activity, internalized amyloid, degraded amyloid, and secreted inflammatory mediators in the same microglial clusters. Prediction: APOE4 lipid-droplet-high LAM will show relatively preserved binding or uptake but impaired lysosomal degradation, and LXR/ABCA1-axis activation or ACAT1/SOAT1 inhibition will rescue degradation more than uptake. Confidence: 0.69.